Piper Sandler upgrades Medtronic to Overweight from Neutral, raises price target to $120 from $85

Piper Sandler upgraded Medtronic to Overweight from Neutral, raising its price target to $120 from $85, a 41.2% increase. The new target implies a 16.6% upside from the Nov 16 close of $102.88.

Original reporting
Published Nov 17, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler upgrades Medtronic to Overweight from Neutral, raises price target to $120 from $85 — source image
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

A higher target and upgrade can influence short-term flows and expectations, but the article does not cite new Medtronic results, guidance, regulatory decisions, or trial data.

02

Market read

Traders may adjust positioning around MDT based on the new Overweight stance and the stated implied upside from the prior close.

03

What to watch

Traders may already have priced in prior expectations; without new company-specific fundamentals, follow-through depends on whether other banks issue similar upgrades or whether price action confirms the target change.

Relevance 7/10Novelty 6/10Timing: today, as the upgrade and price-target change are newly issued

Background

The piece is a sell-side action: Piper Sandler changes its rating and raises its Medtronic price target.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Piper Sandler upgraded Medtronic to Overweight from Neutral and lifted its price target to $120 from $85, implying upside from the Nov 16 close.

Expected impact

Likely upward bias as traders price in improved sell-side stance and target expansion.

Evidence & confidence

The article provides a clear, time-stamped rating and price-target change with implied upside, but it does not include new Medtronic operational or financial data.

Market effects

Could modestly improve sentiment for medical device peers if the market treats the upgrade as a read-through on fundamentals, but the article is single-name.

No direct regional macro or cross-market linkage indicated.

Limited, as the catalyst is a US sell-side note on a single company.

Counterpoint

The move may fade if it is not backed by new Medtronic guidance or data, making it more of a sentiment/positioning catalyst than a fundamental re-rate.

Key entities

  • Medtronic

    Subject of the analyst upgrade and price-target increase.

  • Piper Sandler

    Brokerage issuing the Overweight upgrade and revised price target.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.

$MDTMedAI 8/10

Medtronic to buy Contego Medical for $380M

Medtronic plans to acquire Contego Medical, a privately held medical device company, for $380 million. The deal will expand Medtronic's carotid disease treatments and is expected to close in Q3 of its fiscal year. Medtronic expects minimal dilution to earnings in fiscal 2027 and 2028, then neutrality or accretion after that.